A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Eliquis

  • Handout for Your Patients in Clinic – Which Anticoagulant to Use for DVT and PE

    Stephan Moll, MD writes…  Patients who are on warfarin for a history of DVT or PE  may inquire whether a switch to one of the  new oral anticoagulants is appropriate.  Similarly, many physicians initiate this discussion with their patients. This is, obviously, a detailed discussion and an individualized decision with a number of factors to be considered.…

  • NEJM Publication: Edoxaban for VTE Treatment

    Stephan Moll, MD writes…  Today, Sept 1st, 2013, the New England Journal of Medicine published the phase 3 clinical trial of edoxaban versus warfarin in the treatment of DVT and PE [ref 1]. It showed that edoxaban was as effective as warfarin and led to less clinically relevant bleeding.

  • New Oral Anticoagulants for DVT and PE: Update on FDA Applications

    Stephan Moll, MD writes…   1.  Pradaxa (Dabigatran) Today, August 28th, 2013, it was announced that the FDA is reviewing the application by Boehringer-Ingelheim to get Pradaxa (dabigatran) approved for use in patients with deep vein thrombosis (DVT) and pulmonary embolism (PE) – details here. At present, in the US, Pradaxa is only FDA-approved for…

  • International Coagulation Meeting (ISTH 2013): Highlights

    Stephan Moll, MD writes…  A major international coagulation conference, the bi-annual meeting of the International Society for Thrombosis and Haemostasis (ISTH; http://www.isth.org), took place in Amsterdam, Holland, from June 29th to July 4th, 2013.  The clinically relevant highlights about thrombosis and anticoagulation are summarized below.

  • New Publication: Eliquis (Apixaban) is Effective and Safe in DVT and PE

    Stephan Moll, MD writes…   An important study (AMPLIFY trial) was published today in the New England Journal of Medicine [ref 1]: In a large study of 5395 patients with acute DVT or PE, Eliquis (apixaban) was as effective as warfarin and caused less major bleeding.

  • Antidote for New Oral Xa-Inhibitors (Eliquis, Xarelto): Phase 2 Study

    Stephan Moll, MD writes…. The pharmaceutical company Portola reported today (May 8th, 2013) without many details on the  findings of their phase 2 human volunteer study of their anti-Xa anticoagulant antidote PRT4445 — ClinicalTrials.gov Identifier: NCT01758432 (study description here). In this study, healthy volunteers who had taken Eliquis (Apixaban) received the antidote.  The study showed a “rapid and sustained and dose-related reversal of the…

  • Top 10 Publications on Thrombosis and Anticoagulation from 2012

    Stephan Moll writes… 2012 has been a year with significant progress in the field of venous thromboembolism and anticoagulation.  The three most noteworthy, clinically relevant developments were probably (a) the publication of the new ACCP (American College of Chest Physician) guidelines on antithrombotic therapy in February 2012; (b)  The FDA-approval of rivaroxaban (Xarelto) in November 2012 for the acute…

  • Apixaban (Eliquis) – Hospital Guideline

    Stephan Moll, MD writes… Apixaban (Eliquis®) is FDA-approved for the prevention of  stroke and systemic arterial thromboembolism in patients with atrial fibrillation (Clot Connect discussion of the approval on  Dec 28th, 2012 is here).  Here is the management guideline for apixaban